iNova Corporate Brochure WEB

8/8/2019 iNova Corporate Brochure WEB

1/15

1


2/15

Our Vision

To be recognised as a trustedand respected leader in ourchosen healthcare segments inAsia Pacific and Africa

2


3/15

Contents Introducing iNova Pharmaceuticals 7

Our Mission, Vision & Values 8

Sales, Marketing & Our Therapy Areas 10

New Product Development 11

Manufacturing, Quality & Supply Chain 12

Regulatory Affairs 13

Our Place in the Region 14

How to Contact Us 15

3


4/15

Andrew HowdenChief Executive OfficeriNova Pharmaceuticals

As the global pharmaceutical industry faces increasing challenges, iNova Pharmaceuticals is uniquely

poised to strengthen its position in a highly competitive environment.

We have an established portfolio of consumer healthcare and prescription brands across the fastestgrowing region in the world. We also have appropriate and flexible infrastructure to manage andgrow our business, which enables rapid responses to changing customer needs.

Combined with the strong support of our Board and Management, iNova is building an organisationwith the strategic and operational excellence to rapidly take advantage of opportunities that willbenefit patients, our customers and future business. Above all, we have enthusiastic dedicated teamsacross many countries and sales and marketing partners who are passionate about iNova and thecustomers to whom we are accountable.

Our key focus is to create value for patients and consumers. That is, the value of clinically proven

medicines, value for money to end users, and value in improving their quality of life. In turn, webelieve our focus on patient and consumer value will return as shareholder value.

Patients and Consumers already experience value from iNova products in a number of therapy areasincluding pain management, allergy, dermatology, cardiology, respiratory, sexual health and weightmanagement. We aim to continue strengthening our portfolio with new opportunities that will addpatient value in new therapy areas.

iNova products are providing value for patients and consumers in over 15 countries across the Asia-Pacific and in Africa. We will continue to build our business and reputation in this region with leadingbrands in several therapy areas.

As in all successful organisations, iNovas priority is its people. We will ensure we have a reputation

as a clear market leader in our industry, which can only be achieved with market leading people whohave the highest ethical and professional standards.

So with this in mind, our corporate brochure outlines who we are, our values, people, capabilitiesand therapy areas, as well as future directions for growing our business.

Indeed, as our industry undergoes various changes in the future, we believe iNova will be at theforefront in leading positive change for better outcomes, for all parties.

Andrew Howden

Chief Executive Officer

4


5/15

Our Mission

To improve human healthand well being by providing

valued pharmaceuticalproducts and services

5


6/15

Our Values

At iNova we add value through;

Our people, our products

our integrity and our customers

6


7/15

Introducing iNova Pharmaceuticals

iNova Pharmaceuticals (Australia) Pty Limited is an Australian owned and operated pharmaceutical company that is thecorporate headquarters for iNova Pharmaceuticals (iNova) operations. iNova has leading consumer healthcare andspecialty prescription brands in over 15 countries, including Australia, New Zealand, Asia Pacific and Africa regions.

Borne out of more than 50 years heritage from Riker Laboratories and 3M Pharmaceuticals following the November2006 purchase of 3Ms Asia-Pacific pharmaceutical business by Australian private equity firms Archer Capital andIronbridge Capital. iNova is committed to meeting patient and consumer needs in providing value adding healthcaresolutions that improve peoples health and well being.iNova has a broad spectrum of capabilities involving the companys dedicated business units and business partners toextend product brands into new and existing markets. Our focus is on delivering high quality sales and marketing for theimportant brands we support. We have further key capabilities which include in-licensing, developing and acquiring products,alongside manufacturing, quality and regulatory processes, which are overseen from iNovas corporate headquartersat Thornleigh in Sydney. Our manufacturing site in Sydney is GMP certified and provides products in tablet, capsule,lozenge, liquid, cream and gel formulations for Australia and export markets in Asia, Africa, Europe and the Americas.

iNovas flexible business model also allows the company to enter various partnerships and successfully export to countriessuch as Japan, Korea and China. We therefore work with sales and marketing business partners and pharmaceuticalcompanies in other countries to make our products available to the broader global community. iNova is able to successfullylaunch products (licensed-in or developed in-house) throughout Asia, South Africa, Australia and New Zealand.

Fundamental to strengthening iNovas future product pipeline will be new opportunities bringing patient and consumervalue in selected therapy areas. With its flexibility, established infrastructure and proven track record, iNova is anattractive licensing partner for companies planning to enter the Asia-Pacific and Africa regions.

Overview

7


8/15

Our Mission

To improve human health and well being by providing valued pharmaceutical products and services.

Our VisionTo be recognised as a trusted and respected leader in our chosen healthcare segments in Asia-Pacific

and Africa:

consistently delivering value to patients, customers, employees and shareholders;where people value speed, simplicity and efficient delivery on our promises;accountable for the environmental, social and economic impact of our actions;with a Top 3 selling product in key therapy areas where we compete;with sustainable growth that doubles our business every five years.

8


9/15

At iNova we add value through:

Our People - We are passionate about nurturing people on a professional and personal level

Our Products - We take pride in and are committed to excellence at every stage of the product cycle

Our Integrity - We are ethical in all that we do and sayOur Customers - We listen to customers, understand their needs and aim to consistently meet their expectations

Our key strategic focus is to create value by:

Building pipeline via focused investment in Business Development (acquisitions and in-licensing) inconsumer healthcare and prescription brands for Australasia, Asia-Pacific and Africa regions.

Sharpening sales and marketing execution capabilities to achieve our growth objectives.

Expand geographical reach and create value in key markets including Australia, China, Southeast Asia,South Africa, Korea and Japan to become partner of choice for companies wishing to launch and markettheir product in these regions.

Generate tangible return on capital and investment, managing costs and capital for operating profit (EBITDA)growth.

Our Values

Strategic Focus

9


10/15

iNova is a specialty healthcare organisation with over 100in-house sales and marketing personal operating across theregion, supplemented by contract sales teams within Asia.

A key element of our success is the relentless pursuit ofhigh quality sales and marketing execution in every market.

We aim to be recognised as an industry leader in salesand marketing productivity with high levels of disease stateand product knowledge. Supporting these goals is ourcommitment to ensuring a core competency in effectivesales and marketing execution that drives iNova businessstrategy in creating value for patients and consumers.

High quality interactions with healthcare professionals arepivotal to creating patient and consumer value. Our keycustomers include primary care physicians, dermatologists,pain specialists, weight management specialists, sexual

health physicians, surgeons, and pharmacists, as well askey accounts within the healthcare profession.

Sales and Marketing

Our Therapy AreasiNova has major market leading products in prescription pharmaceuticals and consumer healthcare. Our currentprescription medicines portfolio mainly includes therapies in analgesia, dermatology, cardiology, respiratory, sexualhealth and weight management.

We also have a diverse range of consumer healthcare products as effective treatment options for several conditions.These brands are available in pharmacy and include our recently introduced A to Zep in-licensed range of allergyproducts for hayfever, urticaria and allergic conjunctivitis. The range includes Azep, Eyezep, ZepAllergy andZepClear brands (Eyezep and Azep are registered trademarks of MEDA Pharma GmbH & Co. KG).

In particular, we are committed to providing service, support and educational materials that enable health careprofessionals to optimise health outcomes for their patients. The driving force behind effective sales and marketingimplementation are iNovas people, marketing strategies, innovative customer training programs, sales tactics and agenuine commitment to delivering excellence in all that we do in consistently meeting our customers needs.

10


11/15

Other iNova brands are developed and manufacturedin Australia, and distributed in Australia, Sub-Saharan

Africa and many Asian markets. Our Duro-Tussand Difflam brands hold strong market positionsacross our key categories of cough and sore throat,respectively, and are among the top two selling brandsin several countries. Duro-Tuss (Pholtex in South

Africa) has a 30 year plus heritage, representing todayan extensive range of dry and chesty cough products

in both liquid and lozenge formats. Difflam (Andolexin South Africa) has a strong medicinal heritage withan effective anti-inflammatory active, benzydaminehydrochloride, contained in single and combinationformulations to meet differing health needs. Suitablefor sore throats and painful mouth conditions, Difflamis available in a wide variety of flavours and formats,lozenges, sprays, solutions, gels and gargles thatcaters for choice. Other brands iNova manufactures andmarkets include Metsal, Cal-Sup and Hiprex.

Our products are prescribed by specialist health careproviders and general practitioners across the Regionand supported by pharmacy recommendation.

The origins of our diverse medicines portfolio comefrom a heritage of many years of innovation and, morerecently, in-licensed products. In the development andmanufacturing of our products, quality assurance and

control, operational excellence, integrity and innovationhelp to ensure iNova produces and markets brandsthat meet the most rigorous quality standards.

Looking ahead, there is a strong research drivenpipeline of product innovation that will be used to buildbrands in their existing markets, as well as broadendistribution throughout the Asia-Pacific region.

New Product Development

Our New Product Development team is constantly searching for innovative new prescription and consumer healthcaremedicines in transforming potential opportunities into real healthcare solutions. To enable this, iNovas expertise anddedicated marketing resources in Australia, Asia and South Africa are crucial for the successful introduction of productsinto new markets.

With established therapy franchises in analgesia, allergy, dermatology, weight management, sexual health, respiratory,

and cardiology, as well as a growing and diverse in-licensed pipeline, we aim to bring valued medicines to manymarkets, maximising awareness and utilisation of these products.

An integral part of our business strategy is partnerships, and we invite licensing and co-marketing proposals frompharmaceutical companies seeking growth opportunities in the Asia-Pacific and Southern African regions.

Complementing our in-house licensing expertise is a dedicated team of highly skilled chemists focused on expandingiNovas healthcare consumer portfolio with novel formulations and dose forms that optimise drug delivery and productquality. Among other initiatives, our in-house skills in consumer healthcare product development have resulted inthe successful introduction of many line extensions for Duro-Tuss and Difflam brands, and more innovative newproducts are planned for the future.

11


12/15

Manufacturing and Quality

iNova manufactures pharmaceuticals in liquid and solid dosage forms into a variety of finished product presentationsat the iNova Technology Centre in Sydney. This is a certified Therapeutic Goods Administration (TGA) licensed GMPPharmaceutical Manufacturing Facility with ISO 14001 Environmental Management System Certification.

The iNova Technology Centre represents a major investment in 21st Century energy efficient and environmentallyfriendly technologies and processes. The Centre houses state of the art features such as:

Research and development pilot plant and laboratories;Fully equipped analytical chemistry and microbiology quality control and laboratories;Manufacturing facilities for solids, liquids, cream products, bottles and blister packaging.

With over 170 employees at the Centre including manufacturing staff; mechanical, process and validation engineers,research and product development chemists, analytical chemists and microbiologists, our current production capacityannually includes 570 million tablets; 2.5 million litres of liquid products; 15.6 million blister packing platformsand 6.75 million tubes for topical preparations. iNova employs a full SAP Enterprise Resource Planning system

to ensure efficiencies and effectiveness in delivering the highest level of customer service. This system integratesour manufacturing processes, resource and operations planning, inventory, warehousing and distribution, financialmanagement, purchasing and customer service functions.

Supply ChainiNova supply chain management and logistics include the sales and operations planning process, customer relationshipand warehouse and distribution The synergies of these operations represent a world class supply chain for the ontime and in full supply of products to our markets so that when customers want a product they get it. Our focus is toprovide efficient customer service with minimal lead times in delivering products so customers receive the real valueof our products.

Particular strengths of our supply chain include:

Simplified customer service processes that make it easy to do business with iNova; Continuous improvement in sales and operations planning to enable ongoing forecast accuracy and optimal

product cost and delivery from all supply sources; Centralised warehousing operations that ship iNova products to wholesalers and third party distributors

throughout Australia, New Zealand, Asia-Pacific and Sub-Saharan Africa, as well as other internationalmarkets.

12


13/15

Regulatory and Medical AffairsiNova recognises competitive advantage by beingproactive with compliance, product development andmarketing authorisation requirements. Our in-houseRegulatory and Medical Affairs capability is broadranging, diverse and commercially aware with a team

experienced in new product applications, medicalcommunications and reimbursement processes.

This capability enables iNova to recognise opportunity,competitive advantage and create value by initiatingactivities to ensure timely product approvals in ahighly regulated and regionally diverse industryenvironment. In particular, we have successfullycompleted drug and medical device submissionsand gained approvals across a wide range of therapyareas. These include a first-in-class immune responsemodifier with two different approved dermatology

indications and an indication in sexual health, aswell as fast tracked submissions for numerousconsumer healthcare products in cough and sorethroat categories, novel drugs and medical devices.

Environmental Healthand SafetyEnvironment

iNova is committed to operating an environmentally sustainable business and has a longstanding reputation inthe local and international community for environmental leadership. This is managed through an EnvironmentalManagement System accredited to ISO14001:2004. Resource utilisation is a major focus for our operations groupwith programs in place to reduce energy and water usage. iNova has an ongoing commitment to reducing theamount of waste generated by our operations and supply chain.

Our environmental programs include:

Rollout of a recycling initiative to reduce waste generated on site that ends up in landfill; Upgrade of a waste water treatment plant; Installation of new air compressors to deliver significant savings in electricity usage;

Utilisation of new recycling technology to dispose of waste previously considered non-recyclable.

Occupational Health & Safety

Historically, iNova and its predecessor, 3M Company, have had an ongoing focus to provide a safe and healthy workenvironment for all employees, contractors, visitors and the general public. Specifically, we strive to have a workplacefree of incidents and injury by identifying hazards and reducing risks. We pursue this by continuously improving ourhealth and safety programs and having a collective responsibility for safe work practices driven by all managers,supervisors and staff.

Our activities support the appropriate prescribingand use of approved products and responsiblemarketing promotion via a comprehensive medicalcommunications service for external and internalcustomers. We have high competencies in risk

management processes such as promotionalmaterials review and pharmacovigilance, as well asreimbursement submissions to maximise marketaccess to our brands.

13


14/15

Country Business Partners

Singapore

iNova Offices

South Africa

Japan

Taiwan

PhilippinesMalaysia

Korea

China

AUSTRALIA

Thailand

New Zealand

Australia

iNova Pharmaceuticals (Australia) Pty Limited9-15 Chilvers RoadThornleigh NSW 2120

AustraliaTel: +61 2 9875 6333

South Africa

iNova Pharmaceuticals (Pty) Limited

15e Riley RoadBedfordviewPrivate Bag 3115Bedfordview 2008Republic of South AfricaTel:+27 11 021 4155

Hong Kong

iNova Pharmaceuticals (Hong Kong) LimitedUnit 01, 20th Floor, Millennium City 3,370 Kwun Tong Road, Kwun Tong, KowloonHong Kong

Tel: +852 2117 9228Malaysia

iNova Pharmaceuticals (Singapore) Pte Ltd(Malaysia Branch) (995059W)Level 5, Wisma SamudraNo. 1, Jalan Kontraktor U1/14Hicom-Glenmarie Ind. Park40150 Shah Alam, MalaysiaTel: +603 5569 1278

Philippines

iNova Pharmaceuticals (Philippines).IncUnit 28-B Ayala Life-FGU Center6811 Ayala Avenue, Makati CityPhilippinesTel: +632 840 4741

Singapore

iNova Pharmaceuticals (Singapore) Pte Limited

10 Ubi Crescent02-51 Ubi Techpark, Singapore 408564Tel: +65 6742 3116

Thailand

iNova Pharmaceuticals (Thailand) Limited50 GMM Grammy Place Building 12th Floor,Unit B5, Sukhumvit 21 Road(Asoke),Klongtoeynua, Wattana, Bangkok 10110

ThailandTel: +66 2 665 9055

DKSH Taiwan Ltd10F, No 22, Lane 407, Ti-Ding Blvd,Section 2Neihu Technology ParkTaipei 114, Taiwan, R.O.C.

Distributor/Partner Arrangements with iNovaPharmaceuticals

ChinaJapanKoreaNew Zealand

Our Place in the Region

14


15/15

How to Contact UsCorporate HeadquartersiNova Pharmaceuticals(Australia) Pty Limited

9-15 Chilvers Road

Thornleigh NSW 2120

Australia

PO Box 101

Pennant Hills NSW 2120

Australia

Tel: +61 2 9875 6333

Fax: +61 2 9875 6416

www.inovapharma.com

ABN 88 000 222 408

iNova Corporate Brochure WEB

Documents

Transcript of iNova Corporate Brochure WEB